Mayo Clinic Licenses IP from Qiagen to Develop PCR Test for TB Speciation | GenomeWeb

Mayo Clinic said this week that it has licensed patent rights from Qiagen that will enable Mayo Medical Laboratories to offer a molecular complex speciation test for tuberculosis.

Under the agreement, Mayo has obtained the rights to US Patent No. 7,749,696, entitled "Method and kit for the specific detection of M. tuberculosis," which was issued to Qiagen in July 2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.